Compare GSK plc (GSK) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs International Business Machines Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while International Business Machines Corp trades at $227.13 (market cap $213.50B). The key difference: International Business Machines Corp is far larger — about 2.3× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and International Business Machines Corp for 88 Days on average.
| GSK | IBM | |
|---|---|---|
Market Cap | $91.88B | $213.50B |
Volume | 7,730,529 | 8,908,687 |
Sector | Health | Technology |
52-Week High | $61.18 | $329.23 |
52-Week Low | $43.24 | $205.77 |
Typical Hold Time | 93 Days | 88 Days |
Enterprise Value | $111.88B | $270.64B |
Dividend Yield | 3.9% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
IBM's stock trades at $226.61, up 2.77% today, as recent news of self-hosted deployment for its Bob AI platform and positive sentiment from Accenture's earnings boost investor confidence. The technical picture is bearish with RSI at 71.56 suggesting overbought conditions, while fundamentals show strong revenue growth to $67.54B in 2025 and a net income margin of 15.52%. The company faces cyclical mainframe challenges but maintains a robust $5.5B generative AI consulting pipeline.
IBM presents a mixed outlook with solid profitability and AI growth offset by bearish technical signals and high debt levels. The consensus price target of $255.50 implies 12.8% upside, but investors must weigh competitive pressures in cloud and consulting against its hybrid-cloud strategy. Near-term performance hinges on Q3 2026 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
